SCHEMBL22311355

SCHEMBL22311355

CNC(=O)c1ccc(OCCCCC2CCN(C(=O)[C@](O)(c3cccc(OC)c3)C(F)(F)F)CC2)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.41
▸ NR1H3 Q13133 1/20 0.41
▸ SCN9A Q15858 1/20 0.40
▸ HTR1A P08908 4/20 0.39
▸ DRD2 P14416 4/20 0.39
▸ HTR2A P28223 4/20 0.39
▸ HCRTR1 O43613 1/20 0.38
▸ HCRTR2 O43614 1/20 0.38
▸ CACNA1B Q00975 2/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ REN P00797 2/20 0.36
▸ P2RX7 Q99572 1/20 0.36
▸ PTPN1 P18031 1/20 0.35
▸ GPR119 Q8TDV5 3/20 0.35
▸ THRB P10828 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CCR3 P51677 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22311114 1.00 NR1H2 (0.41) NR1H2NR1H3SCN9AHTR1ADRD2
SCHEMBL30452055 1.00 NR1H2 (0.41) NR1H2NR1H3SCN9AHTR1ADRD2
SCHEMBL30451702 0.89 NR1H2 (0.53) NR1H2NR1H3HCRTR1HCRTR2CACNA1B
SCHEMBL20077052 0.89 NR1H2 (0.42) NR1H2NR1H3SCN9AGPR119KMT2A
SCHEMBL20061107 0.89 NR1H2 (0.53) NR1H2NR1H3HCRTR1HCRTR2CACNA1B
SCHEMBL22284457 0.89 NR1H2 (0.53) NR1H2NR1H3HCRTR1HCRTR2CACNA1B
SCHEMBL22310606 0.89 NR1H2 (0.53) NR1H2NR1H3HCRTR1HCRTR2CACNA1B
SCHEMBL22894966 0.89 NR1H2 (0.40) NR1H2NR1H3SCN9AKMT2ACCR3
SCHEMBL20068562 0.88 NR1H2 (0.39) NR1H2NR1H3SCN9AHCRTR1HCRTR2
SCHEMBL32685385 0.88 NR1H2 (0.39) NR1H2NR1H3SCN9AHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME LLC (US) 2023-05-23 — — US disclosed
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use MERCK SHARP & DOHME LLC (US) 2023-05-23 — — US disclosed
US-20200247754-A1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2020-08-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247754-A1 ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE NR1H2, NR1H3, NR1H4 NR1H2 1/4885NR1H3 2/4885SCN9A 2500/4885
US-11655216-B2 Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use NR1H2, NR1H3, NR1H4 NR1H2 1/4885NR1H3 2/4885SCN9A 2500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback